Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
Belimumab Versus Anifrolumab in Adults with Systemic Lupus Erythematosus: An Indirect Comparison of Clinical Response at 52 Weeks
Lupus Sci. Med 2023;10:e000907 doi 10.1136/lupus-2023-000907
This retrospective study by Neupane, et al. compared belimumab and anifrolumab efficacy at 52 weeks in SLE patients. It concluded that belimumab and anifrolumab have equal efficacy, but further studies would be needed for specific patient demographics.
Litifilimab (BIIB059), a Promising Investigational Drug for Cutaneous Lupus Erythematosus
Expert Opin Investig Drugs 2023;15:1-9 doi 10.1080/13543784.2023.2212154
Cho, et al. discuss the current challenges in the approval of CLE drugs and suggest outcome measures that could streamline the process. They also discuss the pharmacodynamics of litifilimab and the current status of clinical trials.
Baricitinib for Systemic Lupus Erythematosus: a Double-blind, Randomised, Placebo-controlled, Phase 3 trial (SLE-BRAVE-II)
Lancet. 2023 doi: 10.1016/S0140-6736(22)02546-6
Negative results of SLE-BRAVE-II trial show that evidence for the efficacy of baricitinib in SLE is inconclusive.
Lupus Low Disease Activity State Attainment in the Phase 3 TULIP Trials of Anifrolumab in Active Systemic Lupus Erythematosus
Ann Rheum Dis. 2023. doi: 10.1136/ard-2022-222748
Post-hoc anaylsis of TULIP trials shows that, compared with placebo, anifrolumab treatment was associated with earlier, more frequent, and more prolonged and sustained lupus low disease activity state (LLDAS).
New Biologics and Targeted Therapies in Systemic Lupus: From New Molecular Targets to New Indications. A Systematic Review
Joint Bone Spine. 2023.
Systematic review of new biologics and targeted therapies in systemic lupus identifies a highly diversified pipeline of investigational drugs that will hopefully enable a more optimal treat-to-target strategy.
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis
Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322
This 28-week, open-label extension of BLISS-LN found no new safety signals and maintained efficacy with belimumab, in patients with lupus nephritis.
Keywords:
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature
Autoimmun Rev. 2022 doi: 10.1016/j.autrev.2022.103188
Gomez, et al. summarise the effects of biological therapies on SLE patients' health-related quality of life (HRQoL) in RCT and real-life settings, based on a systematic search of the literature.
Keywords:
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685
Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.
Keywords:
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
Ann Rheum Dis 2022;81:962–969 doi: 10.1136/annrheumdis-2021-221847
Bruce, et al. investigate the degree of concordance between BICLA and SRI-4 response across anifrolumab trials (TULIP-1, TULIP-2 and MUSE) in order to better understand drivers of discrepant systemic lupus erythematosus (SLE) trial results.
Impact of belimumab on organ damage in systemic lupus erythematosus
Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901
Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.